Our research reveals that YCWLP exerts therapeutic effects against NASH by inhibiting lipid accumulation and inflammation, which involves the attenuation of pyroptosis via the SHP2/PI3K/NLRP3 pathway. Here, PTPN11 is linked to metabolic dysfunction-associated steatohepatitis.